New Study Shares Benchmarks for Fixed-Dose Combination (FDC) Drug Development
Posted on: Thursday, 5 February 2009, 13:34 CST
Among the many benchmarks included in this study are timeframes for both bioequivalence and clinical evaluation development approaches and the number, types and frequency of tests required. Executives who are responsible for fixed-dose combination (FDC) drug development can use this data to assess the effectiveness and efficiency of their FDC drug product development programs.
To view the study abstract or complimentary summary of the full report "Product Commercialization Excellence: Preparation and Management of Fixed-dose Combination (FDC) Drug Products," click on the following link http://www3.best-in-class.com/re938.htm .
In a benchmarking study that included such influential companies as Abbott, Bayer, Roche, Merck, Pfizer, and Sanofi-Aventis, many key topics were covered, including:
-- Bioequivalence Approach -- Clinical Evaluation Approach -- Lessons Learned -- FTEs and Complexity Among the key metrics gathered in this report are: -- Past, Present and Future Number of FDC Drugs in Development -- Additive vs. Synergistic Effects -- Bioequivalence vs. Clinical Evaluation (Preferences and reasons why) -- Starting Development Prior vs. Post Patent Expiration -- Use of External Consultants -- Bioequivalence -- Timeframe from Conception to Final Formulation Launch -- Clinical Evaluation -- Timeframe from Conception to Final Formulation Launch -- Bioequivalence -- Timeframe from Initiating Formulation Development to Final Formulation Launch -- Clinical Evaluation -- Timeframe from Initiating Formulation Development to Final Formulation Launch -- Bioequivalence -- Multiple Metrics -- Clinical Evaluation -- Multiple Metrics -- Number of Drugs, FTEs and Timeframe to Reach First/Second Pilot PK Study -- Number of Drugs, FTEs and Timeframe to Reach Pivotal BE Study -- Number of FTEs in Analytical Development -- Timeframe from Initiating Development Work to CTM Manufacturing for Class 1/2/4 drugs For more information on this study or the Best Practices, contact
ABOUT BEST PRACTICES, LLC
Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.
SOURCE Best Practices, LLC
Source: PR Newswire
Related Articles
- Methylgene Reports Clinical Data From a Phase II Study Evaluating MGCD0103 in Relapsed or Refractory Non-Hodgkin Lymphomas...
- ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
- Fourth ACTEMRA(TM) (Tocilizumab) Phase III Study Demonstrates Significant Clinical Benefit in RA Patients
- Eight Studies Evaluating Cytyc's Novasure(R) System Presented at AAGL Meeting
- Twelve Studies Evaluating Cytyc's MammoSite(R) Radiation Therapy System Presented at ASTRO Annual Meeting
- Celleration, Inc. Announces the Publication of a Clinical Study: Evaluation of the Effectiveness of MIST Ultrasound Therapy for the Healing of Chronic Wounds
- Studies Evaluating Eloxatin-Based Regimens in Gastrointestinal Cancers Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
- eCopy Presents Software Connections and Laserfiche With Software Developer Best Practices Award
- Thirteen Studies Evaluating Cytyc's NovaSure(R) System Presented at AAGL Annual Meeting
- Twelve Studies Evaluating Cytyc's ThinPrep(R) Imaging System Presented at National Scientific Meeting
 |
 |
User Comments (0)
RSS Feeds